Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025

NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients

View Full Paper
Ask AI
Bookmark
Share

Authors

QPQuang Toan PhamFTFarzaneh TamnanlooMMMarie-Agnès M’Callum

Discussion

Loading...

Member takes

Overview

Observational analysis evaluated NTBC dosing in 99 HT1 patients, indicating protective effects and oncogenic risks.

Key Points

  • The study confirmed that 50 μmol/L of NTBC effectively prevents cellular damage in hereditary tyrosinemia type 1.
  • In a cohort of 99 patients, the established dosing was validated, and treatment efficacy was demonstrated, indicating positive outcomes.
  • Despite treatment, about 10% of genes linked to hepatocellular carcinoma remained dysregulated, raising concerns for long-term risks.
  • An in vitro model using iPSC-derived hepatocytes revealed key disease mechanisms related to FAH deficiency and NTBC treatment.

Cite This Study

Pham et al. (2025) studied this question.

synapsesocial.com/papers/68e70da790569dd607ee5a59https://doi.org/10.1101/2025.10.06.680797
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1edgeR : a Bioconductor package for differential expression analysis of digital gene expression data2009 · 45,480 citations
  2. 2Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day2017 · 21 citations